The effectiveness of the new cardioplegic solution in isolated coronary bypass surgery

Objective: to study the effectiveness of a new cardioplegic solution in comparison with Custodiol solution during coronary artery bypass graft surgery (CABG).

Material and methods. A total of 146 patients with ischemic heart disease who underwent isolated CABG surgery in conditions

of artificial circulation in the period from April 2018 to August 2021 were selected. A cohort of patients was randomly divided into 2 groups: Group 1 included 88 patients who underwent isolated CABG using blood isothermal cardioplegia with a new cardioplegic solution; Group 2 consisted of 58 patients who underwent isolated CABG accompanied by cardioplegia with Custodiol solution. As part of the preoperative diagnosis, each patient was assigned a complex of laboratory and instrumental studies. The analysis of the results was based on a comparison of intraoperative and perioperative (24 hours after surgery) indicators in both groups.

Results. Cases of unstable angina pectoris significantly prevailed in the first group (63.5% vs 32.76% p=0.001). The frequency of angina pectoris, on the contrary, was higher in the second group (63.8% vs 35.3%, p=0.001). In both groups, the values of cardiac output were satisfactory (59.24±7.31 vs 57.95±8.57; p=0.561). Lactate levels were lower in Group 1 than in Group 2. Patients from the first group left intensive care units on average 2 times faster than those who received Custodiol in cardioplegia. The number of bed days was lower in Group 1 patients. The frequency of postoperative complications was comparable in both groups.

Conclusion. In the postoperative period, there are no statistically significant differences in the frequency of complications after the use of isothermal blood cardioplegia with a new cardioplegic solution and cardioplegia with Custodiol during CABG surgery.

1. Habib R. [et al.] CABG Versus PCI: Greater Benefit in Long-Term Outcomes With Multiple Arterial Bypass Grafting. J Am Coll Cardiol. 2015;66(13):1417-27.

2. Shikova Yu. V. [et al.] Razrabotka sostava i tekhnologii kardioplegicheskogo sredstva. Meditsinskii al'manakh.2015; (37):122-125. (in Engl.)

3. Averina T.B., Movsesyan R.R., Shebaev G.A. Sovremennye strategii zashchity miokarda u detei (Modern strategies for protecting the myocardium in children). Detskie bolezni serdtsa i sosudov; 2007(5):45-53. (in Russ.)

4. Abah U. [et al.] Is cold or warm blood cardioplegia superior for myocardial protection?Interact Cardiovasc Thorac Surg. 2012; 14(6):848–855. (in Engl.)

5. Festa A. [et al.] The relation of body fat mass and distribution to markers of chronic inflammation. Int. J. Obes. Relat. Metab. Disord. Nature Publishing Group. 2001;25:1407–1415. (in Engl.)

6. Hearse D.J., Braimbridge M.V., Jynge P. Cardioplegic solutions in clinical use. Protection of the ischemic myocardium: cardioplegia. New York: Raven Press Books, Ltd.1981:341– 352. (in Engl.)

7. Kumada Y. [et al.] Long-term clinical outcome after surgical or percutaneous coronary revascularization in hemodialysis patients. Circ J. 2014;78:986-992. (in Engl.)

8. Bayandin N.L. Сrystalloid hypothermic and blood normothermic cardioplegia. Clinical and experimental surgery. Petrovsky journal. 2020; 8(1):80-89.